Top 10 Oncology Capital Raises in the U.S. – June 16th-30th, 2025
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Aptevo Therapeutics, a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer, received $8.01 million of development capital through a private placement.
- Cyclacel Pharmaceuticals, a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases, received $3 million of development capital through a private placement.
- INmune Bio, a clinical-stage biotechnology company, received approximately $19 million of development capital through a private placement.
Merger/Acquisition
-
- GlycoMimetics, a clinical-stage biotechnology company, was acquired by Crescent Biopharma.
- Kineta, a clinical stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, was acquired by TuHURA Biosciences.
- Kronos Bio, a clinical-stage biopharmaceutical company, was acquired by Concentra, a subsidiary of MJ Acquisition, for $59.7 million.
Later Stage VC
-
- EtiraRx, a biopharma research company that develops products to overcome tumor heterogeneity, raised $2.4 million in venture funding.
- LinusBio, a precision exposome medicine platform that analyzes the molecular impact of environmental exposures on health, raised $3 million in venture funding from YAC Holdings.
Seed
-
- Inversion Therapeutics, an oncology biotech platform that discovers and progress therapies against previously untapped cancer mechanisms, raised $5 million in seed funding in the form of convertible debt in a deal led by Red Tree Venture Capital.
- P1 Trials, a community-based oncology investigative site that transforms cancer care by facilitating the discovery and development of therapies through advanced Phase 1 clinical trials, raised $1.65 million in seed funding.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
